Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
Tweet
Share
E-mail
A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little
(Reuters) -Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc, spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers.
Spokespeople for both companies said in emails to Reuters that they had no special arrangements with the company.
Mangoceuticals did not respond to request for comment.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shilpi Majumdar)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US packaged food makers could help cut diet-related deaths, study shows
- Indonesia court reduces Gojek founder's sentence to 9 years in appeal hearing
- BOJ could raise rates every quarter, ex-policymaker says
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
